Head-To-Head Contrast: Clearmind Medicine (CMND) vs. Its Competitors

Risk & Volatility

Clearmind Medicine has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Clearmind Medicine’s competitors have a beta of 3.64, indicating that their average share price is 264% more volatile than the S&P 500.

Insider and Institutional Ownership

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Clearmind Medicine and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-129.21%	-61.15%
Clearmind Medicine Competitors	-3,409.82%	-235.83%	-32.89%

Earnings and Valuation

This table compares Clearmind Medicine and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Clearmind Medicine	N/A	-$5.26 million	-0.64
Clearmind Medicine Competitors	$9.95 billion	$135.48 million	-7.87

Clearmind Medicine’s competitors have higher revenue and earnings than Clearmind Medicine. Clearmind Medicine is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Clearmind Medicine competitors beat Clearmind Medicine on 5 of the 9 factors compared.

Clearmind Medicine Company Profile

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.